BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Synlogic (SYBX)SynlogicConference / presentation

- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass. , Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral,

Open original release

Related news

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

NAMSNewAmsterdam Pharma2026-04-08 12:00 EST

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

ALGSAligos Therapeutics2026-02-23 13:00 EST

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

SYBXSynlogic2024-02-02 17:00 EST

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

SYBXSynlogic2024-01-04 12:00 EST

Synlogic Provides Corporate Update and Outlook for 2024

MISTMilestone Pharmaceuticals Inc.2026-03-16 12:13 EST

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

EMBCEmbecta2025-12-18 22:00 EST

embecta to Participate at the J.P. Morgan 2026 Healthcare Conference

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

SYBXSynlogic2024-02-20 17:15 EST

Synlogic Adopts Limited Duration Stockholders Rights Plan

Stock data

Close
0.67 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States